New York, August 29, 2024 - PRISM MarketView - The National Institutes of Health (NIH) is directing $2.4 million towards research on psychedelics to address methamphetamine use disorders. This funding responds to a sharp rise in deaths from methamphetamine, with fatal overdoses increasing nearly fivefold from 2015 to 2022. The grant recipients, including researchers from UCSD’s Center for Psychedelic Research, LSU Health Shreveport, and the Medical College of Wisconsin, aim to explore the potential of psychedelics like psilocybin in treating addiction.
Research will delve into the mechanisms behind psychedelics’ benefits, particularly focusing on the serotonin receptor 5-HT2A. The ultimate goal is to develop drugs that offer therapeutic benefits without inducing psychedelic effects, enabling more practical use.
This funding arrives amid increasing meth-related overdose deaths in the U.S., with methamphetamine surpassing opioids as the primary drug detected in overdose cases in some regions. In 2022, 34,022 people died from overdoses involving psychostimulants, a substantial rise from 5,716 in 2015.
Past studies have shown psychedelics may provide new treatment pathways for substance use disorders. Recent analyses have highlighted psilocybin’s potential in reducing heavy drinking in alcohol use disorder cases. Emerging research also suggests that full-spectrum psychedelic mushroom extracts could be more effective than synthetic alternatives, pointing to an “entourage effect” akin to cannabis.
Additional findings show single-dose psilocybin does have a lower risk of causing paranoia, with temporary side effects like headaches. Research from 2019 also suggests CBD could aid in treating substance use disorders, including methamphetamine-related ones.
The ongoing efforts seek to develop psychedelics-related drugs that separate therapeutic benefits from psychedelic experiences, supported by government funding, such as a $26.9 million DARPA project for treating mental health and substance abuse without major side effects.
To learn about emerging stocks in the space visit the PRISM Emerging Psychedelic Index.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities